The story of the erectile dysfunction drug presents a challenging picture for shareholders. While the initial introduction generated substantial profits, the end of its intellectual property protection opened the door to generic alternatives, click here dramatically reducing revenue. This poses a particular dilemma for pharmaceutical companies depe

The legacy of Viagra, and its creator copyright, presents a complex case study for investors. Originally a blockbuster drug, generating billions in income, its exclusivity period created a wave of knock-off medications, significantly eroding its position . While certain businesses may try to capitalize on male sexual dysfunction, the current landsc